These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28653421)

  • 1. Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
    Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
    Transfusion; 2017 Oct; 57(10):2359-2365. PubMed ID: 28653421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
    Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
    Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
    Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
    Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.
    Sato K; Ishiyama K; Aoki G; Maruyama H; Tsuji N; Tanabe M; Zaimoku Y; Sato H; Yamazaki H; Yamaguchi M; Takami A; Nakao S
    Int J Hematol; 2019 Dec; 110(6):648-653. PubMed ID: 31542851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.
    Reményi P; Gopcsa L; Marton I; Réti M; Mikala G; Pető M; Barta A; Bátai A; Farkas Z; Borbényi Z; Csukly Z; Bodó I; Fábián J; Király A; Lengyel L; Piukovics K; Torbágyi E; Masszi T
    Adv Ther; 2014 Apr; 31(4):451-60. PubMed ID: 24687301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.
    Aggarwal V; Sabry W; Elemary M; Bosch M; Danyluk P; Mondal P; Stakiw J
    Curr Oncol; 2021 Apr; 28(3):1571-1580. PubMed ID: 33922026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Pham T; Patil S; Fleming S; Avery S; Walker P; Wei A; Curtis D; Stuart G; Klarica D; O'Brien M; Morris K; Das T; Bollard G; Muirhead J; Coutsouvelis J; Spencer A
    Transfusion; 2015 Nov; 55(11):2709-13. PubMed ID: 26173921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of biosimilar filgrastim and originator filgrastim for peripheral blood stem cell mobilization for allogeneic hematopoietic stem cell transplantation.
    Shahzad M; Amin MK; Bellman P; Al-Ramahi J; Noor J; Vyas A; Mahmoudjafari Z; McGuirk M; DeJarnette S; Ahmed N; Abdallah AO; Shune L; Singh AK; McGuirk JP; Abhyankar S; Mushtaq MU
    Transfusion; 2024 Aug; 64(8):1402-1406. PubMed ID: 38847196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
    Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
    J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma.
    Samaras P; Pfrommer S; Seifert B; Petrausch U; Mischo A; Schmidt A; Schanz U; Nair G; Bargetzi M; Taverna C; Stupp R; Stenner-Liewen F; Renner C
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):74-80. PubMed ID: 25278456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
    Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
    Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients.
    Lefrère F; Bernard M; Audat F; Cavazzana-Calvo M; Belanger C; Hermine O; Arnulf B; Buzyn A; Varet B
    Leuk Lymphoma; 1999 Nov; 35(5-6):501-5. PubMed ID: 10609787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs.
    Ria R; Gasparre T; Mangialardi G; Bruno A; Iodice G; Vacca A; Dammacco F
    Bone Marrow Transplant; 2010 Feb; 45(2):277-81. PubMed ID: 19584820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
    Chin-Yee IH; Keeney M; Stewart AK; Belch A; Bence-Buckler I; Couban S; Howson-Jan K; Rubinger M; Stewart D; Sutherland R; Paragamian V; Bhatia M; Foley R
    Bone Marrow Transplant; 2002 Dec; 30(12):851-60. PubMed ID: 12476276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
    Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
    Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.